to determine whether long-term sulfonylurea therapy ameliorates glucose homeostasis in patients with niddm predominantly by improving insulin secretion or by improving insulin action , we evaluated changes in fasting plasma glucose concentrations , intravenous glucose tolerance , glucose-stimulated insulin secretion , facilitation of glucose disposal by exogenous insulin , and erythrocyte insulin receptor binding before and after prolonged ( congruent to 4 mo ) administration of tolazamide to 18 patients with niddm .
C0040372
tolazamide
C0011860
niddm